Some patients with RA also receive other biological drugs that suppress IL-6 signaling and B-cells or targeted synthetic disease-modifying anti-rheumatic disease which inhibit Janus kinase activity and have decreased cardiovascular mortality among patients with RA in recent years [30]. This evidence concerns the gene IL6 and rheumatoid arthritis.